期刊
NEUROBIOLOGY OF AGING
卷 33, 期 3, 页码 479-487出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2010.03.023
关键词
Positron emission tomography; Brain; Serotonin; Serotonin transporter; Imaging; 5-HT; Serotonin 2A; Dementia; Atrophy; [F-18] altanserin; [C-11]DASB
资金
- The Lundbeck Foundation
- Rigshospitalet
- Danish Medical Research Council
- EC [LSHB-CT-2005-512146]
In patients with Alzheimer's disease (AD), postmortem and imaging studies have revealed early and prominent reductions in cerebral serotonin 2A (5-HT2A) receptors. To establish if this was due to a selective disease process of the serotonin system, we investigated the cerebral 5-HT2A receptor and the serotonin transporter binding, the latter as a measure of serotonergic projections and neurons. Twelve patients with AD (average Mini Mental State Examination [MMSE]: 24) and 11 healthy age-matched subjects underwent positron emission tomography (PET) scanning with [F-18]altanserin and [C-11]N, N-Dimethyl-2-(2-amino-4-cyanopheylthio)benzylamine ([C-11]DASB). Overall [F-18]altanserin binding was markedly reduced in AD by 28%-39% (p = 0.02), whereas the reductions in [C-11]DASB binding were less prominent and mostly insignificant, except for a marked reduction of 33% in mesial temporal cortex (p = .0005). No change in [C-11]DASB binding was found in the midbrain. We conclude that the prominent reduction in neocortical 5-HT2A receptor binding in early AD is not caused by a primary loss of serotonergic neurons or their projections. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据